As shown in Figure 2a, the PFS of patients with CDC42 mutations in NSCLC patients was significantly longer than that of wild type patients (p = 3.8E‐2, HR = 0.49, 95% CI = 0.25–0.97). Here, CDC42 is linked to non-small cell lung carcinoma.